{
    "organizations": [],
    "uuid": "d62a18a80dc50869f11cab1ee6295265f7acd7b7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-says-successfully-com/brief-novo-nordisk-says-successfully-completes-first-trial-for-oral-semaglutide-idUSASM000JLY",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - NOVO NORDISK SAYS:\n* SUCCESSFULLY COMPLETES THE FIRST PHASE 3A TRIAL, PIONEER 1, WITH ORAL SEMAGLUTIDE\n* ‍TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL PRINCIPLE BY DEMONSTRATING SIGNIFICANT AND SUPERIOR IMPROVEMENTS IN HBA (LONG-TERM BLOOD SUGAR) FOR ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO​\n* 14 MG DOSE OF ORAL SEMAGLUTIDE DEMONSTRATED SIGNIFICANT AND SUPERIOR WEIGHT LOSS VERSUS PLACEBO, WEIGHT LOSS WAS OBSERVED FOR 7 MG AND 3 MG DOSES BUT DID NOT REACH STATISTICAL SIGNIFICANCE​\n* ‍WE ARE VERY ENCOURAGED BY RESULTS OF PIONEER 1 TRIAL, WHICH CONFIRM UNPRECEDENTED ORAL EFFICACY OF SEMAGLUTIDE THAT WAS REPORTED IN PHASE 2 CLINICAL TRIAL IN TYPE 2 DIABETES​\n* ‍WE LOOK FORWARD TO PROVIDING DATA FROM REMAINING NINE PIONEER TRIALS THROUGHOUT THIS YEAR AND AN EXPECTED REGULATORY SUBMISSION IN 2019​ SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Jacob Gronholt-Pedersen)\n ",
    "published": "2018-02-22T17:51:00.000+02:00",
    "crawled": "2018-02-23T15:34:11.079+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novo",
        "nordisk",
        "say",
        "successfully",
        "completes",
        "first",
        "phase",
        "3a",
        "trial",
        "pioneer",
        "oral",
        "semaglutide",
        "achieved",
        "primary",
        "objective",
        "according",
        "primary",
        "statistical",
        "principle",
        "demonstrating",
        "significant",
        "superior",
        "improvement",
        "hba",
        "blood",
        "sugar",
        "three",
        "dos",
        "oral",
        "semaglutide",
        "compared",
        "mg",
        "dose",
        "oral",
        "semaglutide",
        "demonstrated",
        "significant",
        "superior",
        "weight",
        "loss",
        "versus",
        "placebo",
        "weight",
        "loss",
        "observed",
        "mg",
        "mg",
        "dos",
        "reach",
        "statistical",
        "encouraged",
        "result",
        "pioneer",
        "trial",
        "confirm",
        "unprecedented",
        "oral",
        "efficacy",
        "semaglutide",
        "reported",
        "phase",
        "clinical",
        "trial",
        "type",
        "look",
        "forward",
        "providing",
        "data",
        "remaining",
        "nine",
        "pioneer",
        "trial",
        "throughout",
        "year",
        "expected",
        "regulatory",
        "submission",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "jacob"
    ]
}